Traders purchased shares of Johnson & Johnson (NYSE:JNJ) on weakness during trading hours on Friday. $222.43 million flowed into the stock on the tick-up and $114.14 million flowed out of the stock on the tick-down, for a money net flow of $108.29 million into the stock. Of all equities tracked, Johnson & Johnson had the 2nd highest net in-flow for the day. Johnson & Johnson traded down ($0.12) for the day and closed at $125.03

JNJ has been the topic of a number of recent research reports. Leerink Swann reiterated a “buy” rating on shares of Johnson & Johnson in a report on Wednesday, April 20th. Royal Bank Of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a report on Sunday, April 17th. Deutsche Bank AG reiterated a “buy” rating on shares of Johnson & Johnson in a report on Wednesday, April 6th. Wells Fargo & Co. reiterated a “buy” rating and issued a $115.00 target price on shares of Johnson & Johnson in a report on Thursday, April 7th. Finally, Argus raised their price objective on Johnson & Johnson from $116.00 to $130.00 and gave the company a “buy” rating in a research note on Wednesday, April 20th. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating and ten have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $117.04.

The company has a market capitalization of $343.91 billion and a price-to-earnings ratio of 23.30. The firm’s 50-day moving average price is $119.61 and its 200-day moving average price is $110.34.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 19th. The company reported $1.74 earnings per share for the quarter, beating analysts’ consensus estimates of $1.68 by $0.06. The firm earned $18.50 billion during the quarter, compared to the consensus estimate of $17.98 billion. On average, equities research analysts expect that Johnson & Johnson will post $6.69 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, August 19th. Shareholders of record on Friday, August 5th will be issued a $0.29 dividend. This represents a $1.16 dividend on an annualized basis and a yield of 0.93%.

In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 3,000 shares of the stock in a transaction dated Tuesday, June 7th. The stock was sold at an average price of $115.79, for a total value of $347,370.00. Following the transaction, the chief accounting officer now owns 28,725 shares of the company’s stock, valued at $3,326,067.75. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Gary J. Pruden sold 9,735 shares of the stock in a transaction dated Tuesday, June 7th. The shares were sold at an average price of $116.03, for a total value of $1,129,552.05. Following the completion of the transaction, the vice president now directly owns 43,630 shares in the company, valued at approximately $5,062,388.90. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have recently bought and sold shares of the company. Heritage Wealth Advisors increased its position in Johnson & Johnson by 3.3% in the fourth quarter. Heritage Wealth Advisors now owns 9,944 shares of the company’s stock worth $1,021,000 after buying an additional 317 shares in the last quarter. Lourd Capital LLC boosted its stake in shares of Johnson & Johnson by 8.3% in the fourth quarter. Lourd Capital LLC now owns 11,115 shares of the company’s stock worth $1,142,000 after buying an additional 851 shares during the last quarter. Eidelman Virant Capital boosted its stake in shares of Johnson & Johnson by 11.8% in the fourth quarter. Eidelman Virant Capital now owns 11,623 shares of the company’s stock worth $1,193,000 after buying an additional 1,231 shares during the last quarter. Wedgewood Investors Inc. PA boosted its stake in shares of Johnson & Johnson by 0.4% in the fourth quarter. Wedgewood Investors Inc. PA now owns 11,883 shares of the company’s stock worth $1,221,000 after buying an additional 50 shares during the last quarter. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its stake in shares of Johnson & Johnson by 9.9% in the fourth quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 13,032 shares of the company’s stock worth $1,339,000 after buying an additional 1,179 shares during the last quarter.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.